Einstein/Montefiore Department of Medicine

Department Faculty

Dr. Harry Shamoon, M.D.

Harry Shamoon, M.D.

Senior Associate Dean for Clinical and Translational Research

Professor, Department of Medicine (Endocrinology)

Director, Institute for Clinical and Translational Research

Areas of Research: I lead the Einstein-Montefiore Institute for Clinical and Translational Research (ICTR). My own research programs have focused type 1 and type 2 diabetes, funded via mechanistic physiology grants and NIH clinical trials.

Professional Interests

Dr. Shamoon is Associate Dean for Clinical and Translational Research, Director of the Harold and Muriel Block Institute for Clinical & Translational Research at Einstein and Montefiore (ICTR), and tenured Professor of Medicine (Endocrinology, Diabetes and Metabolism).

The ICTR is home to the Clinical and Translational Science Award (CTSA) program funded by the NIH's National Center for Advancing Translational Sciences (NCATS). The CTSA consortium, a group of ~60 leading US medical research institutions works together to improve the way biomedical research is conducted, and shares a common vision of accelerating laboratory discoveries and engaging communities in clinical research to bring discoveries and prevention into practice. It is also focusing on the training the next generation of clinical investigators. The ICTR represents the research partnership between Albert Einstein College of Medicine and the Montefiore Health System that support the CTSA vision. The ICTR is a hub for many collaborations in clinical and translational projects involving Einstein-Montefiore research centers, departments, and faculty.

Dr. Shamoon's research includes laboratory studies of the mechanisms and treatment for defective counterregulation of hypoglycemia in diabetes. His lab was the first to establish the causal link between reduced epinephrine and glucagon secretion and impaired hepatic glucose production in response to hypoglycemia in type 1 diabetes. Further studies elucidated the stimulus-specificity of the responses to hypoglycemia and the resultant defects in glucose counterregulation, the existence of hepatic "autoregulation" by glucose per se, and the role of glucokinase activation in restoring impaired counterregulation in diabetes. His group has also established the contributions of hepatic glycogen metabolism and gluconeogenesis to glucose counterregulation in humans using in vivo MR spectroscopy, and have examined potential drug targets to restore counterregulatory defenses.

Dr. Shamoon also led major diabetes clinical trials at Einstein, including the Diabetes Control and Complications Trial, the landmark study that established the benefits of intensive glycemic control in type 1 diabetes, and the Diabetes Prevention Program in type 2 diabetes. Dr. Shamoon has been elected to the American Society of Clinical Investigation (ASCI) and the American Association of Physicians (AAP).

More Information About Dr. Harry Shamoon

Harold and Muriel Block Institute for Clinical and Translational Research at Einstein and Montefiore

Material in this section is provided by individual faculty members who are solely responsible for its accuracy and content.

Albert Einstein College of Medicine
Jack and Pearl Resnick Campus
1300 Morris Park Avenue
Belfer Building, Room 302
Bronx, NY 10461

Tel: 718.430.3382

Research Information

In the News

Woman's Day features advice from Dr. Harry Shamoon on the right way to search for health information online.

More media coverage